Century Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on January 22, 2026, for Century Therapeutics, Inc., a Delaware corporation and emerging growth company. The report details the results of a Special Meeting of stockholders and a subsequent regulatory update regarding Nasdaq listing compliance.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The report focuses exclusively on corporate governance actions and regulatory status.
Material Changes and Events
- Stockholder Vote: On January 22, 2026, stockholders approved a proposal to amend the Company's Certificate of Incorporation to authorize a reverse stock split with a ratio between 1-for-5 and 1-for-30.
- Voting Results: Out of 87,405,311 outstanding shares (as of the November 25, 2025 record date), 55,089,478 votes were cast "For," 5,361,020 "Against," and 27,055 "Abstentions."
- Nasdaq Compliance: On the same day, the Company received notification from Nasdaq that it has regained compliance with Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share.
Outlook, Management Commentary, and Risks
Management has announced that, due to the regained compliance with Nasdaq listing standards, the Company does not intend to effect the reverse stock split that was approved by stockholders. The filing notes that the Company is now in compliance with all applicable continued listing standards. No other risks, contingencies, or unusual items were disclosed in this specific report.
Key Facts for Investor Verification
- Verify the current trading price of the stock (Symbol: IPSC) to confirm sustained compliance with the $1.00 minimum bid price requirement.
- Confirm that the Board of Directors has formally communicated the decision not to proceed with the reverse stock split to the market.
- Review the Definitive Proxy Statement on Schedule 14A (filed December 2, 2025) for detailed context on the original proposal.